July 25, 2012 13:45 ET

Global Diabetes Rates to Catapult to 552 Million by 2030

NEW YORK, NY--(Marketwire - Jul 25, 2012) - cites in its newly published "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report that global diabetes rates will catapult to 552 million by 2030. For more information, visit:

Diabetes can be categorized into two main modalities: Type I diabetes, i.e., juvenile onset diabetes, and Type II diabetes, i.e., adult onset diabetes. The vast majority of incidences of diabetes are Type II diabetes, which is strongly linked to health problems such as cardiovascular disease (CVD), obesity, decreased renal function, deterioration of vision and neuropathy. The global market for oral anti-diabetics and human insulins will nearly double over the next ten years, reaching close to $70 billion by 2020.

The "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report covers:

  • Diabetes Mellitus
  • Metabolic Syndrome
  • Stress-Induced Hyperglycemia
  • Anti-Hypertensive Drugs
  • Cholesterol Management Drugs
  • Anticoagulants
  • Sulfonylureas
  • Meglitinides
  • Biguanides
  • Thiazolidinediones (TZDs)

The "Diabetes, Metabolic Syndrome and Cardiovascular Disease" report examines companies manufacturing diabetes equipment and supplies in the world. Companies covered include: A. Menarini, Abbott, Amgen, AstraZeneca, Bayer, BodyMedia, Cybermedical, Debiotech, DexCom, Echo, Eksigent, Eli Lilly, Elixir, Flamel, GlaxoSmithKline, Insulet, iSense, Isis, Johnson & Johnson, KYORIN, M-Biotech, Medtronic, Merck, Merck KGaA, MicroIslet, Mitsubishi Tanabe, Nipro, Novartis, Novo Nordisk, Novocell, ONO, Orexigen, Pfizer, Roche, Sanofi-Aventis, Sensors for Medicine and Science, Siemens, Smiths, SOOIL, Takeda, TheraFuse, U.S. Diagnostics, VeraLight, Vivus and Ypsomed.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit:

About is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information